Advice

in the absence of a submission from the holder of the marketing authorisation

paclitaxel albumin (Abraxane®) is not recommended for use within NHS Scotland.

Indication under review: in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.
 

Download detailed advice49KB (PDF)

Download

Medicine details

Medicine name:
paclitaxel albumin (Abraxane)
SMC ID:
1071/15
Indication:
in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.
Pharmaceutical company
Celgene Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
08 June 2015